57
Participants
Start Date
December 31, 2024
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2026
XELOX+Sintilimab+HBOT
"Patients will receive the XELOX regimen, consisting of oxaliplatin (130 mg/m² IV on Day 1) and capecitabine (1000 mg/m² orally twice daily for 14 days, repeated every 3 weeks), combined with sintilimab (200 mg IV on Day 1 every 3 weeks) and hyperbaric oxygen therapy (HBOT) administered alongside the XELOX regimen. Treatment will be administered for 4 to 6 cycles.~Following the initial treatment phase, patients will be evaluated for response. If disease progression is observed, patients will exit the study and receive subsequent treatments as deemed appropriate. For patients with stable disease or a response to therapy, maintenance treatment with capecitabine and sintilimab will continue until the occurrence of a study endpoint or other specified criteria."
RECRUITING
West China Hospital of Sichuan University, Chengdu
NOT_YET_RECRUITING
West China Hospital, Sichuan University, Chengdu
West China Hospital
OTHER